Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) (Avonex China)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01181115
Recruitment Status : Completed
First Posted : August 13, 2010
Last Update Posted : September 16, 2013
Sponsor:
Information provided by (Responsible Party):
Biogen

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The study is designed to determine the effect of weekly intramuscular (IM) administration of 30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and T2-weighted cranial magnetic resonance imaging (MRI) lesions in Chinese patients with clinically diagnosed (using revised McDonald criteria) relapsing multiple sclerosis (MS).

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: Avonex Phase 3

Detailed Description:

This is a multicenter, open-label, safety study to support registration of Avonex in China by providing data on the effect of weekly IM administration of 30mcg Avonex on safety parameters in Chinese patients with clinically diagnosed relapsing MS. This study will also include an intra-subject exploratory comparison of pre-treatment MRI (at -3 months and at month 0) and post -treatment MRI (at month 3 and month 6). Up to 60 subjects with relapsing forms of MS will be recruited to approximately 6 sites in China.

The study period will consist of screening, a 6 month open-label treatment period, and follow up at 30 days post-dosing. There will be a total of 8 clinic visits and 1 telephone contact.

Screening: will be determined 3 months +/- 7 days prior to subjects' first dose of Avonex on Day 1, at which time a screening MRI with and without Gd-enhancement will be performed.

Treatment Period: consists of eligible patients undergoing pre-dosing assessments and receiving the first dose of Avonex on day 1. Subjects will have a brain MRI within 48 hours prior to the first injection of Avonex.

Weekly doses of open-label Avonex 30mcg IM will be administered for 24 consecutive weeks for a total of 25 injections per subject. Subjects or their caregivers will be allowed to self-inject after successful completion of appropriate IM injection training.

Subjects will return to the clinic at weeks 6, 12, 18 and 24 for safety and laboratory assessments (including blood sample collection for pharmacodynamic (neopterin) and immunogenicity testing), and clinician injection site assessments. Subjects will undergo brain MRI with and without Gd enhancement at week 12 and week 24. Subjects will perform injection site pain assessments on day 1 and at weeks 6, 12, 18, and 24 recording results on a visual analog scale. Subjects who prematurely discontinue Avonex may remain in the study and continue protocol-scheduled visits/evaluations (with the exception of subject and clinician injection site assessments and neopterin sample collection.

Subjects who experience new or worsening symptoms suggestive of an MS relapse will have a neurological worsening visit within 5 days following onset of symptoms. Treatment of confirmed MS relapses will follow a protocol-specified regimen.

Post treatment period: subjects will undergo follow-up assessment at week 24 (at 24+/- 8 hours following their last Avonex injection, if applicable). Subjects will have a telephone follow up contact conducted 30 (+/- 7 days) after their last study visit to assess AEs and use of concomitant medications.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Avonex (Interferon Beta-1a) in Chinese Subjects With Relapsing Multiple Sclerosis
Study Start Date : April 2010
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Active treatment
Interferon treatment for MS
 Drug: Avonex
Interferon treatment for MS


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The number and proportion of subjects with adverse events (AEs) [ Time Frame: 24 weeks ]
  2. Assessment of clinical laboratory parameters [ Time Frame: 24 weeks ]
  3. Assessment of vital signs and physical examinations [ Time Frame: 24 weeks ]
  4. Assessment of electrocardiogram (ECG) [ Time Frame: 24 weeks ]
  5. Assessment of immunogenicity [ Time Frame: 24 weeks ]
  6. Incidence of depression [ Time Frame: 24 weeks ]
  7. Incidence of flu-like symptoms [ Time Frame: 24 weeks ]
  8. Subject assessment of injection site pain [ Time Frame: 24 weeks ]
  9. Clinical assessment of the injection site [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Assess safety of Avonex by evaluating changes in the Expanded Disability Status Scale (EDSS) score over time [ Time Frame: 24 weeks ]
  2. Number of Gd-enhancing lesions on brain MRI scans taken after 3 and 6 months following Avonex treatment [ Time Frame: at month 3 and month 6 ]
  3. Number of new or newly enlarging T2-weighted lesions on brain MRI scans taken after 3 and 6 months following Avonex treatment [ Time Frame: at month 3 and month 6 ]
  4. Volume of T2-weighted lesions on brain MRI scans taken after 6 months following initiation of Avonex treatment [ Time Frame: month 6 ]
  5. Assess pharmacodynamic response to Avonex by evaluating the change from baseline in serum levels of neopterin [ Time Frame: 24 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to understand risks of study and provide informed consent.
  • Must be Chinese, aged 18 to 55 years inclusive at time of consent.
  • Must have diagnosis of relapsing MS of 3 months duration at time of screening visit.
  • Must have at least 1 documented MS attack within 3 years of Day 1.
  • Must have EDSS score of 0 to 5 inclusive at screening visit.
  • All male subjects & female subjects of child-bearing potential must practice effective contraception during the study.

Exclusion Criteria:

  • Have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS.
  • Have had a clinical MS attack within the 50 days prior to Day 1, and or the subject has not stabilized from a previous attack in the opinion of the Investigator.
  • The subject is unable to undergo a brain MRI scan for any reason.
  • The subject's screening and Day 1 MRIs are both normal (negative) for lesions consistent with MS (Gd-enhancing lesions are not required, but one of the 2 MRIs should be consistent with MS).
  • History of severe allergic or anaphylactic reactions.
  • Known allergy to any component of the Avonex Formulation.
  • History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal or other major disease.
  • Subjects with a history of malignant disease, including solid tumors, and hematologic malignancies (except basal cell and squamous cell carcinomas of the skin that have been completely excised and considered cured).
  • History of seizure disorder or unexplained blackouts OR history of a seizure within 6 months prior to Day 1.
  • History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 6 months prior to Day 1. Note: subjects receiving ongoing antidepressant therapy will not be excluded from the study unless the medication has been increased within the 6 months prior to Day 1.
  • Clinically significant abnormal ECG values as determined by the Investigator.
  • Known history of human immunodeficiency virus (HIV).
  • Known history of, or positive test result for hepatitis C virus (test for hepatitis C virus antibody HCV Ab) or hepatitis B virus (test for Hepatitis B surface Antigen HBsAg) and/or Hepatitis B Core Antibody (HBcAb).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01181115


Locations
Layout table for location information
China
Research Site
Baotou, China
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Chengdu, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Nanchang, China
Research Site
Shanghai, China
Research Site
Taiyuan, China
Research Site
Xi'an, China
Sponsors and Collaborators
Biogen
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT01181115    
Other Study ID Numbers: 108MS301
First Posted: August 13, 2010    Key Record Dates
Last Update Posted: September 16, 2013
Last Verified: November 2011
Keywords provided by Biogen:
Chinese Patients
Relapsing MS
Safety
Avonex
 Tolerability
Gadolinium
Interferon Beta 1a
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
 Immune System Diseases
Interferon beta-1a
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents